NCT00030576View on ClinicalTrials.gov

Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Head and Neck Cancer
Interventions
DRUG

cisplatin

DRUG

erlotinib hydrochloride

Trial Locations (6)

L8V 5C2

Margaret and Charles Juravinski Cancer Centre, Hamilton

K7L 3N6

Queen's University, Kingston

N6A 4L6

Cancer Care Ontario-London Regional Cancer Centre, London

K1H 1C4

Ottawa Regional Cancer Centre, Ottawa

M5G 2M9

Princess Margaret Hospital, Toronto

H2L-4M1

Centre Hospitalier de l'Universite de Montreal, Montreal

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University Health Network, Toronto

OTHER

NCT00030576 - Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | Biotech Hunter | Biotech Hunter